Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose

Affiliations

• ¹ Pfizer, Drug Safety Research and Development, San Diego, CA, 92121, USA. bart.jessen@pfizer.com.
• ² Eli Lilly, Nonclinical Safety Assessment, Indianapolis, IN, USA.
• ³ Clinical Pharmacology & Safety Sciences, AstraZeneca Pharmaceuticals, Waltham, MA, 02451, USA.
• ⁴ Eisai Inc., Global Nonclinical Regulatory, Nutley, NJ, 07110, USA.
• ⁵ Development Science, UCB, Inc., Cambridge, MA, 02140, USA.
• ⁶ Nonclinical Safety Evaluation, Bristol Myers Squibb, Princeton, NJ, 08540, USA.
• ⁷ GlaxoSmithKline, IVIVT, Collegeville, PA, 19426, USA.